Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators

Yamaya, Takafumi; Hee, Hwang Moon; Aoyagi, Takayuki; Ogimoto, Tatsuya; Yamada, Naoki; Ishikawa, Ryoichi; Nakai, Erika; Nishi, Kenta; Yoshimura, Chie; Nishizaka, Yasuo

doi:10.1016/j.rmcr.2019.100866

Cited by 7 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although interstitial involvement of lung tissue is more frequent in the context of pulmonary adverse events attributed to ICIs, isolated airway disease has also been observed [84]. Recently, Mitropoulou et al [85] described 2 cases of severe airway disease induced by treatment with ICI, without interstitial involvement.…”

Section: Diagnosismentioning

confidence: 99%

Immune Checkpoint Inhibitor-Related Pneumonitis

et al. 2020

View full text Add to dashboard Cite

Immune checkpoint inhibitors are novel agents that have been proved efficacious in a variety of cancer types, but they are associated with a unique set of organ-specific, immune-related adverse events. Among them, immune-related pneumonitis requires special attention because it is difficult to diagnose and potentially lethal. Accumulating real-world epidemiological data suggest that immune-related pneumonitis is more frequent than previously reported. Its diagnosis requires exclusion of other causes and assessment of radiographic features on high-resolution CT of the chest. Management of immune-related pneumonitis is based on the use of immunosuppressants. Future research should be focused on finding predictive biomarkers for immune-related pneumonitis as well as optimizing its management.

show abstract

Section: Diagnosismentioning

confidence: 99%

Immune Checkpoint Inhibitor-Related Pneumonitis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Rarely, airway disease without interstitial involvement has been observed. [40][41][42] These patients may present with asthma-like symptoms, bronchial wall thickening, and micronodules with a "tree in bud" appearance. Pleural effusion can also be present Grade III ICI pneumonitis with OP pattern.…”

Section: Imaging Featuresmentioning

confidence: 99%

Imaging Features of Pulmonary Immune-related Adverse Events

Pozzessere

Lazor

Jumeau

et al. 2021

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Pulmonary immune-related adverse events represent rare but potentially severe side effects of immunotherapies. Diagnosis is often challenging, as symptoms and imaging features are not specific and may mimic other lung diseases, thus potentially delaying appropriate patient management. In this setting, an accurate imaging evaluation is essential for a prompt detection and correct management of these drug-induced lung diseases. The purpose of this article is to review the different types of pulmonary immune-related adverse events, describe their imaging characteristics on both high-resolution computed tomography and positron emission tomography/computed tomography and stress their underlying diagnostic challenge by presenting the mimickers.

show abstract

“…Pembrolizumab-related obstructive bronchiolitis has also been described in a patient who presented with dry cough while receiving pembrolizumab for lung adenocarcinoma. The diagnosis of bronchiolitis was made by radiography and lung biopsy findings and his symptoms improved after the discontinuation of pembrolizumab and with administration of erythromycin, an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting β2 agonist [55].…”

Section: Airway Diseasementioning

confidence: 99%

Pulmonary adverse events due to immune checkpoint inhibitors: A literature review

Georgakopoulou

Garmpis

Mermigkis

et al. 2021

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Cancer immunotherapy aims to stimulate the immune system to fight against tumors, utilizing the presentation of molecules on the surface of the malignant cells that can be recognized by the antibodies of the immune system. Immune checkpoint inhibitors, a type of cancer immunotherapy, are broadly used in different types of cancer, improving patients’ survival and quality of life. However, treatment with these agents causes immune-related toxicities affecting many organs. The most frequent pulmonary adverse event is pneumonitis representing a non-infective inflammation localized to the interstitium and alveoli. Other lung toxicities include airway disease, pulmonary vasculitis, sarcoid-like reactions, infections, pleural effusions, pulmonary nodules, diaphragm myositis and allergic bronchopulmonary aspergillosis. This review aims to summarize these pulmonary adverse events, underlining the significance of an optimal expeditious diagnosis and management.

show abstract

Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators

Cited by 7 publications

References 17 publications

Immune Checkpoint Inhibitor-Related Pneumonitis

Immune Checkpoint Inhibitor-Related Pneumonitis

Imaging Features of Pulmonary Immune-related Adverse Events

Pulmonary adverse events due to immune checkpoint inhibitors: A literature review

Contact Info

Product

Resources

About